Neutralization<unk>  is a monoclonal antibody therapy that is infused intravenously into patients with Ebola virus disease.<unk>  is a neutralizing antibody, meaning it binds to a protein on the surface of Ebola virus that is required to infect cells. Specifically,<unk>  neutralizes infection by binding to a region of the Ebola virus envelope glycoprotein that, in the absence of<unk> , would interact with virus's cell receptor protein, Niemann-Pick C1 (NPC1). This "competition" by<unk>  prevents Ebola virus from binding to NPC1 and "neutralizes" the virus's ability to infect the targeted cell. Effector function Antibodies have antigen-binding fragment (Fab) regions and constant fragment (Fc) regions. The Neutralization of virus infection occurs when the Fab regions of antibodies binds to virus antigen(s) in a manner that blocks infection. Antibodies are also able to "kill" virus particles directly and/or kill infected cells using antibody-mediated "effector functions" such as opsonization, complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity and antibody-dependent phagocytosis. These effector functions are contained in the Fc region of antibodies, but is also dependent on binding of the Fab region to antigen. Effector functions also require the use of complement proteins in serum or Fc-receptor on cell membranes.<unk>  has been found to be capable of killing cells by antibody-dependent cell-mediated cytotoxicity. Other functional killing tests have not been performed.
Ansuvimab
Regdanvimab
Atoltivimab
Obiltoxaximab
Sotrovimab
Odesivimab
Nirsevimab
Lirentelimab